Market Place
Sourcing Support
Olverembatinib Overcomes CML Resistance, Well Tolerated in Report
21 Nov 2024 //
PR NEWSWIRE
Takeda`s Iclusig wins first-line FDA nod to treat Ph+ALL
20 Mar 2024 //
FIERCE BIOTECH
Takeda Announces U.S. FDA Approval of sNDA) for ICLUSIG® (ponatinib)
19 Mar 2024 //
BUSINESSWIRE
Ponatinib Plus Low-Dose Chemotherapy Improves MRD– CR Rates in Ph+ ALL
24 Aug 2023 //
ONCLIVE
Takeda`s Iclusig tops Novartis` Gleevec decisively in Ph+ALL
15 Feb 2023 //
FIERCE PHARMA
FDA Confirms Paragraph IV Patent Litigation for Ponatinib Hydrochloride
13 Jan 2023 //
FDA
Phase 3 Trial of ICLUSIG Met Primary Endpoint in Diagnosed Ph+ ALL
17 Nov 2022 //
BUSINESSWIRE
FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant
18 Dec 2020 //
CANCERNETWORK
FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant
18 Dec 2020 //
CANCERNETWORK
Marker Reports Interim Results of its MultiTAA-Specific T Cell Therapy
29 May 2020 //
PRNEWSWIRE
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program
29 May 2020 //
TAKEDA
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib)
29 May 2020 //
BUSINESSWIRE
Takeda to Showcase Growing Pipeline & Diversified Portfolio of Oncology Products
16 May 2019 //
BUSINESSWIRE
Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome
11 Oct 2018 //
GOV UK
Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome
11 Oct 2018 //
GOV UK
Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome
11 Oct 2018 //
GOV UK
EMA Assessmt & Procedural Steps for Incyte`s Iclusig (ponatinib)
10 Oct 2018 //
EMA
EMA Assessment of Incyte Biosciences` Iclusig (ponatinib) & Procedural steps
10 Oct 2018 //
EMA
F-Prime, Atlas lead cancer startup Akrevia to $30M A round
27 Sep 2018 //
FIERCE BIOTECH
Takeda Publishes Final Data from ICLUSIG® (ponatinib) Ph 2 Trial in Blood
23 Mar 2018 //
BUSINESSWIRE
Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib)
22 Mar 2018 //
BUSINESSWIRE
Biotech Startup Prelude Therapeutics Gets Grant to Triple Its Workforce
15 Aug 2017 //
BIOSPACE
NICE backs routine use of Incyte’s leukaemia drug
14 Feb 2017 //
PHARMATIMES
Ariad Stays Mum on Layoffs After Takeda`s $5.2 Billion Takeover
28 Jan 2017 //
BIOSPACE
A Peek Behind the Curtain of the Ariad-Takeda Deal
21 Jan 2017 //
BIOSPACE
Staggering` Price Hikes Resulted In $5 Billion Payday For Ariad Pharma Investors
12 Jan 2017 //
FORBES
Takeda Shells Out Whopping $5.2B & its Fledgling Med Brigatinib
10 Jan 2017 //
FIERCE PHARMA
Sanders Seeks Ariad Data on Cancer Drug Price Hikes
21 Oct 2016 //
STAT
Why Incyte, Biogen and BioMarin are Hot Acquisition Targets
12 Oct 2016 //
BIOSPACE
BCR-ABL Tyrosine Kinase Inhibitors - Risk of Hepatitis B Reactivation
06 May 2016 //
HEALTH CANADA
Health Canada Require Updated Warning on Gleevec Labeling for Brand and Generics
05 May 2016 //
TWOFOUR INSIGHT
BCR-ABL Tyrosine Kinase Inhibitors
04 May 2016 //
HEALTH CANADA
Can Baxalta hold off Shire with its own bid for Ariad?
31 Aug 2015 //
FIERCE PHARMA
Seven New Drugs OK`d For NHS Scotland
14 Apr 2015 //
PHARMA TIMES
Activists Ready to Fight for Ariad CEO`s Ouster: CNBC
13 Feb 2015 //
FIERCE PHARMA
